Drug Type Bispecific antibody |
Synonyms ALK-1/VEGF bispecific antibody (Kintor Pharmaceuticals) |
Target |
Action inhibitors |
Mechanism ALK1 inhibitors(Activin receptor-like kinase 1 inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | China | 07 Mar 2022 |